Adocia (ADOCY) Stock Price, News & Analysis

Company Overview

Adocia is a clinical‐stage biotechnology company focused on the development of innovative formulations of therapeutic proteins for metabolic diseases, most notably diabetes. The company’s proprietary BioChaperone® platform uses small molecular excipients to stabilize and optimize the pharmacokinetic and pharmacodynamic properties of peptides and proteins. Adocia’s primary area of research centers on improving the onset, duration and patient convenience of insulin and other hormone therapies.

Adocia’s pipeline includes a range of investigational products designed to address unmet needs in both type 1 and type 2 diabetes. Lead candidates feature ultra‐rapid insulin and long‐acting insulin analogs formulated to achieve faster absorption and more consistent blood glucose control. The company is also exploring combination therapies that pair insulin with other peptide hormones, as well as once‐weekly formulations of existing treatments. Clinical trials have been conducted in Europe, North America and Asia, demonstrating the platform’s versatility across multiple therapeutic areas.

Founded in 2004 and headquartered in Lyon, France, Adocia leverages partnerships with global pharmaceutical companies to advance its programs toward commercialization. The company maintains a multidisciplinary team of research, regulatory and clinical experts who oversee studies in key markets worldwide. Adocia’s collaborations and licensing agreements are designed to accelerate late‐stage development, manufacture scalable drug formulations and prepare for market entry in major geographies.

Key Stats

• Today's Range: $11.80 to $11.80
• 50-Day Range: $11.80 to $11.80
• 52-Week Range: $9.80 to $11.80
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $231.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ADOCY
• CIK: N/A
• Web: www.adocia.com
• Phone: 33-04-72-61-06-10
• Fax: 33-04-72-36-39-67
• Employees: 78
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $13.12 million
• Price / Sales: 17.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.21) per share
• Price / Book: -56.19

Miscellaneous

• Outstanding Shares: 19,610,000
• Free Float: N/A
• Market Cap: $231.40 million
• Optionable: Not Optionable
• Beta: -0.12